A Chinese neuroscientist, Zilong Qiu, has been dismissed from his leadership post following a government investigation into a gene-editing trial that resulted in the death of a 6-year-old girl. According to Chinese state broadcaster CCTV, Shanghai authorities announced on Friday that Qiu was removed as deputy director of the Songjiang Research Institute at Shanghai Jiao Tong University. The investigation found that Qiu failed to report the child's death in research published in the journal Nature on February 18.
The incident began in January 2025, when a hospital ethics committee approved a gene-editing trial to treat Snijders Blok-Campeau syndrome, a rare neurodevelopmental condition. The 6-year-old girl, whose condition was described as non-life-threatening, died in March 2025 due to complications from the experimental gene therapy. The hospital subsequently terminated the study, and an investigation into the trial's conduct was launched.
Official findings, as reported by Science and Retraction Watch in July, indicated that the trial proceeded under a regulatory provision that bypassed the need for national-level approval. Investigators concluded that Qiu's team did not properly inform the hospital about safety concerns identified during earlier primate testing. Additionally, the girl's parents, who paid over $800,000 to fund the experiment, stated they were not adequately informed of the risks. "We did not realize how unusual and dangerous many of the arrangements were," the girl's father told Science.
The disciplinary actions include a five-year suspension for Qiu from participating in any scientific projects. He has also been recorded in a government database for "serious breaches of research integrity." Another researcher on Qiu's team was fired and received a five-year suspension, while several other individuals at the hospital where the trial occurred were also punished. The hospital previously paid a fine to a local health authority following the death, though the exact amount was described only as "modest."
The situation sets a precedent for how Chinese authorities oversee gene-editing research following the 2018 case of He Jiankui, who was imprisoned for creating gene-edited babies. This new investigation underscores the potential for regulatory gaps in hospital-approved trials that avoid national oversight. What happens next depends on the implementation of the five-year bans on the researchers involved and any further changes to how local health authorities monitor experimental genetic treatments. The exact effective date of all punishments was not specified in the reports.